(19)
(11) EP 2 338 902 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
03.08.2011 Bulletin 2011/31

(43) Date of publication:
29.06.2011 Bulletin 2011/26

(21) Application number: 10010873.7

(22) Date of filing: 29.04.2008
(51) International Patent Classification (IPC): 
C07K 14/26(2006.01)
A61K 39/395(2006.01)
 C07K 16/12(2006.01)
A61P 31/04(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 02.05.2007 EP 07107344

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08736618.3 / 2152731

(71) Applicant: Intercell AG
1030 Vienna (AT)

(72) Inventors:
  • Bakshi, Sharmila
    Kenton, Harrow HA3 0LR Middlesex (GB)
  • Cipps, Thomas
    1140 Vienna (AT)
  • Hanner, Markus
    3013 Pressbaum (AT)
  • Pikalo, Jutta
    9162 Strau (AT)
  • Satke, Christina
    1060 Vienna (AT)
  • Nagy, Eszter
    1070 Vienna (AT)
  • Lundberg, Urban
    3013 Pressbaum (AT)
  • Wakefield, Dagmar
    NSW 2483 Ocean Shores (AU)
  • Meinke, Andreas
    3013 Pressbaum (AT)
  • Noiges, Birgit
    1050 Vienna (AT)
  • Stierschneider, Ulrike
    1070 Vienna (AT)
  • von Gabain, Alexander
    1180 Vienna (AT)

(74) Representative: Bösl, Raphael Konrad 
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München
81675 München (DE)

 
Remarks:
The complete document including Reference Tables and the Sequence Listing can be downloaded from the EPO website
Remarks:
This application was filed on 27-09-2010 as a divisional application to the application mentioned under INID code 62.
 


(54) Klebsiella antigens


(57) The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection. More specifically such antigens are produced by or associated with bacterial pathogens causing nosocomial infections or bacterial infections caused by Klebsiella pneumoniae.